Device for treating cardiac arrest

• US 9,402,952 B2
• Filed: 10/11/2010
• Issued: 08/02/2016
• Est. Priority Date: 10/12/2009
• Status: Active Grant

• Current Assignee: ResuSciTec GmbH
• Original Assignee: ResuSciTec GmbH
• Inventors: Beyersdorf, Friedhelm
• Primary Examiner(s): Wiest, Philip R
• Assistant Examiner(s): KLEIN, BENJAMIN JACOB
• Application Number:
  US13/501,248
• Publication Number:
  US 20120203158A1
• Time in Patent Office: 2,122 Days
• Field of Search: 604 401- 11
• US Class Current: 1/1
• CPC Class Codes: A61B 5/14539 for measuring pH
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/14557 specially adapted to extracorporeal circuits
• CPC Class Codes: A61M 1/34 Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
• CPC Class Codes: A61M 1/3639 Blood pressure control, pressure transducers specially adapted therefor
• CPC Class Codes: A61M 1/3666 Cardiac or cardiopulmonary bypass, e.g. heart-lung machines
• CPC Class Codes: A61M 1/3687 Chemical treatment A61M1/3675 takes precedence
• CPC Class Codes: A61M 1/369 Temperature treatment
• CPC Class Codes: A61M 2005/006 for gases, e.g. CO2
• CPC Class Codes: A61M 2005/14272 for emergency, field or home use, e.g. self-contained kits to be carried by the doctor
• CPC Class Codes: A61M 2202/0208 Oxygen
• CPC Class Codes: A61M 2202/04 Liquids
• CPC Class Codes: A61M 2202/0468 non-physiological
• CPC Class Codes: A61M 2202/0486 Glucose
• CPC Class Codes: A61M 2202/06 Solids
• CPC Class Codes: A61M 2202/07 Proteins
• CPC Class Codes: A61M 2205/3368 Temperature
• CPC Class Codes: A61M 2205/52 with memories providing a history of measured variating parameters of apparatus or patient
• CPC Class Codes: A61M 2205/75 with filters
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 2230/005 : Parameter used as control input for the apparatus
• CPC Class Codes: A61M 2230/20 : Blood composition characteristics
• CPC Class Codes: A61M 2230/201 : Glucose concentration
• CPC Class Codes: A61M 2230/202 : partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
• CPC Class Codes: A61M 2230/205 : partial oxygen pressure (P-O2)
• CPC Class Codes: A61M 2230/208 : pH-value
• CPC Class Codes: A61M 2230/30 : Blood pressure A61M2230/04 takes precedence
• CPC Class Codes: A61M 2230/50 : Temperature
• CPC Class Codes: A61M 2250/00 : Specially adapted for animals
• CPC Class Codes: A61M 5/1408 : in parallel, e.g. manifolds, sequencing valves access sites A61M39/02; tube connectors A61M39/10
• CPC Class Codes: A61M 5/142 : Pressure infusion, e.g. using pumps
• CPC Class Codes: A61M 5/16827 : controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths infusion of multiple fluids without using a controller A61M5/1407
• CPC Class Codes: A61M 5/1723 : using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61M 5/44 : having means for cooling or heating the devices or media
• CPC Class Codes: A61P 7/08 : Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04

Abstract

The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).

Claims

1. In a system providing treatment of cardiac arrest by withdrawing blood from a patient'"'"'s or an animal'"'"'s circulatory system during the cardiac arrest and introducing at least modified blood containing the withdrawn blood to which at least one substance has been added to provide whole body reperfusion of the circulatory system with the modified blood during the treatment of cardiac arrest comprising blood analysis means, for connection during the treatment of the cardiac arrest to the blood withdrawn from the circulatory system, for determining during the treatment of the cardiac arrest, a plurality of parameters of the blood including at least pO2, pCO2, and pH representing a current condition of the patient or animal during treatment of the cardiac arrest and an output representing the determination during the treatment of the cardiac arrest, storage means for storing during the treatment of the cardiac arrest at least two substances from which the at least one substance is selected for the treatment of the cardiac arrest, means for selecting during the treatment of the cardiac arrest, based on the analysis, a type and quantity of the at least one substance from the storage means which is added to the withdrawn blood to form the modified blood, which upon introduction into the circulatory system during the treatment of the cardiac arrest lessens or prevents ischemic tissue damage and means for introducing during the treatment of the cardiac arrest at least the modified blood into the circulatory system which provides the whole body reperfusion of the circulatory system during the treatment of the cardiac arrest which lessens or prevents the ischemic tissue damage during the treatment of the cardiac arrest, the method comprising:

withdrawing the blood from the circulatory system during the cardiac arrest;

analyzing the blood withdrawn from the circulatory system with the blood analysis means during the cardiac arrest and determining during the treatment of the cardiac arrest the plurality of parameters of the blood including at least pO₂, pCO₂, and the pH;

selecting, based on the determination of at least the pO2, the pCO2 and the pH, during the treatment of the cardiac arrest, a type and quantity of the at least one substance from the stored substances which is added to the blood to form the modified blood which upon introduction of the modified blood into the circulatory system during the treatment of the cardiac arrest lessens or prevents ischemic tissue damage; and

introducing at least the modified blood into the circulatory system during the treatment of the cardiac arrest which provides the whole body reperfusion of the circulatory system with the modified blood to treat the cardiac arrest which lessens or prevents ischemic tissue damage during the treatment of the cardiac arrest.

2. A method in accordance with claim 1, comprising:

pumping a regulated flow of the modified blood into the circulatory system during the treatment of the cardiac arrest.

3. A method in accordance with claim 1, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

selecting a type and quantity of the at least one substance to form the modified blood is also based on the representation.

4. A method in accordance with claim 2, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the cardiac arrest; and

wherein;

selecting a type and quantity of the at least one substance to form the modified blood is also based on the representation.

5. A method of treating cardiac arrest, by withdrawing blood from the patient'"'"'s or animal'"'"'s circulatory system during the treatment of the cardiac arrest and introducing at least modified blood containing the blood to which at least one substance has been added during the treatment of the cardiac arrest to provide whole body reperfusion of the circulatory system with the modified blood during the treatment of the cardiac arrest comprising:

withdrawing the blood from the circulatory system during the treatment of the cardiac arrest;

analyzing the blood withdrawn from the circulatory system during the treatment of the cardiac arrest to determine a plurality of parameters of the blood including at least the pO₂, pCO₂, and pH representing a current condition of the patient or animal during the cardiac arrest;

storing at least two substances from which at least one substance is selected;

selecting, based on the determination of at least the pO2, the pCO2 and the pH, during the treatment of the cardiac arrest a type and quantity of at least one of the at least two stored substances which is added to the withdrawn blood to form the modified blood, which upon introduction into the circulatory system during the treatment of the cardiac arrest, lessens or prevents ischemic tissue damage during the treatment of the cardiac arrest; and

introducing the modified blood into the circulatory system during the treatment of the cardiac arrest which provides the whole body reperfusion of the circulatory system with the modified blood which lessens or prevents the ischemic tissue damage during the treatment of the cardiac arrest.

6. A method in accordance with claim 5, comprising:

pumping the modified blood into the circulatory system.

7. A method in accordance with claim 5, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing a representation of the at least one physiological parameter during the treatment of cardiac arrest; and

wherein;

the selection of the at least one substance to form the modified blood is also based on the representation.

8. A method in accordance with claim 6, comprising:

monitoring at least one physiological parameter of the patient or animal during the cardiac arrest and providing output representation of the at least one physiological parameter during the treatment of cardiac arrest; and

wherein;

the selection of the at least one substance to form the modified blood is also based on the representation.

9. A method in accordance with claim 5, comprising:

mixing at least one stored substance with the withdrawn blood to form the modified blood during the treatment of cardiac arrest.

10. A method in accordance with claim 6, comprising:

mixing at least one stored substance with the withdrawn blood to form the modified blood during the treatment of cardiac arrest.

11. A method in accordance with claim 7, comprising:

mixing at least one stored substance with the withdrawn blood to form the modified blood during the treatment of cardiac arrest.

12. A method in accordance with claim 8, comprising:

mixing at least one stored substance with the withdrawn blood to form the modified blood during the treatment of cardiac arrest.

13. A method in accordance with claim 5, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

14. A method in accordance with claim 6, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

15. A method in accordance with claim 7, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

16. A method in accordance with claim 8, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

17. A method in accordance with claim 9, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

18. A method in accordance with claim 10, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

19. A method in accordance with claim 11, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

20. A method in accordance with claim 12, comprising:

storing a plurality of substances in solid, liquid or gaseous form, from which the at least one substance is selected by the type and quantity to be mixed with the blood to form the modified blood during the treatment of cardiac arrest.

21. A method in accordance with claim 5, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

22. A method in accordance with claim 6, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

23. A method in accordance with claim 7, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

24. A method in accordance with claim 8, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

25. A method in accordance with claim 9, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

26. A method in accordance with claim 10, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

27. A method in accordance with claim 11, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

28. A method in accordance with claim 12, comprising:

selecting during the treatment of cardiac arrest the at least one substance from at least one of an alkaline buffer solution, an acidic buffer solution, substances affecting sodium, potassium and/or calcium content, blood-thinning substances, free radical trapping agents, glutamate, aspartame, heart-rhythm-stabilizing substances, substances influencing leukocyte count and osmotically-active substances including salts, glucoses and proteins.

29. A method in accordance with claim 7, wherein:

monitoring the at least one physiological parameter during the treatment of cardiac arrest comprises monitoring at least one of mean arterial pressure, central nervous pressure, pulmonary artery pressure, oxygen saturation and blood temperature.

30. A method in accordance with claim 8, wherein:

monitoring the at least one physiological parameter during the treatment of cardiac arrest comprises monitoring at least one of mean arterial pressure, central nervous pressure, pulmonary artery pressure, oxygen saturation and blood temperature.

31. A method in accordance with claim 7, wherein:

the at least one physiological parameter which is monitored during the treatment of cardiac arrest comprises at least one of mean arterial pressure, central nervous pressure, pulmonary artery pressure, oxygen saturation and blood temperature and the method further comprises;

generating a representation of at least one of the arterial pressure, the central nervous pressure, the pulmonary artery pressure, the oxygen saturation and the blood temperature; and

wherein

the selection of the type and quantity of the at least one substance from storage for forming the modified blood is also based on the representation.

32. A method in accordance with claim 8, wherein:

the at least one physiological parameter which is monitored during the treatment of cardiac arrest comprises at least one of mean arterial pressure, central nervous pressure, pulmonary artery pressure, oxygen saturation and blood temperature and the method further comprises;

generating a representation of at least one of the arterial pressure, the central nervous pressure, the pulmonary artery pressure, the oxygen saturation and the blood temperature; and

wherein

the selection of the type and quantity of the at least one substance from storage for forming the modified blood is also based on the representation.

33. A method in accordance with claim 5, wherein:

the plurality of parameters of the blood further includes potassium content, calcium content, base excess, lactate value or glucose content.

34. A method in accordance with claim 6, wherein:

the plurality of parameters of the blood further includes potassium content, calcium content, base excess, lactate value or glucose content.

35. A method in accordance with claim 5, comprising:

providing during the treatment of cardiac arrest a heat exchanger in a blood flow path, disposed between a point of withdrawal of the blood from the circulatory system and point of return of at least the modified blood into the circulatory system which, based on the analysis, controls a temperature of at least the modified blood introduced into the circulatory system to perform whole body reperfusion of the circulatory system.

36. A method in accordance with claim 7, comprising:

providing during the treatment of cardiac arrest a heat exchanger in a blood flow path, disposed between a point of withdrawal of the blood from the circulatory system and point of return of at least the modified blood into the circulatory system which, based on the analysis, controls a temperature of at least the modified blood introduced into the circulatory system to perform whole body reperfusion of the circulatory system.

37. A method in accordance with claim 5, comprising:

controlling, based on the analysis, at least one of pressure, flow rate and temperature of at least the modified blood introduced into the circulatory system to perform whole body reperfusion of the circulatory system.

38. A method in accordance with claim 7, comprising:

controlling, based on the analysis, at least one of pressure, flow rate and temperature of at least the modified blood introduced into the circulatory system to perform whole body reperfusion of the circulatory system.

39. A method in accordance with claim 5, comprising:

providing during the cardiac arrest an oxygen enrichment and depletion means in a blood flow path, disposed between a point of withdrawal of the blood from the circulatory system and a point of return of at least the modified blood into the circulatory system for analyzing an amount of oxygen in the withdrawn blood and controlling with the oxygen and the depletion means, based on an analysis of oxygen in the withdrawn blood, oxygen present in at least the modified blood which is introduced into the circulatory system to provide whole body reperfusion of the circulatory system.

40. A method in accordance with claim 7, comprising:

providing during the cardiac arrest an oxygen enrichment and depletion means in a blood flow path disposed between a point of withdrawal from the circulatory system and a point of return of at least the modified into the circulatory system for analyzing an amount of oxygen in the withdrawn blood and controlling with the oxygen and the depletion means, based on an analysis of oxygen in the withdrawn blood, oxygen present in at least the modified blood which is introduced into the circulatory system to provide whole body reperfusion of the circulatory system.

41. A method providing treatment of cardiac arrest, circulatory arrest or stroke by withdrawal of blood from a patient'"'"'s or an animal'"'"'s circulatory system during the cardiac arrest, circulatory arrest or stroke and introducing at least modified blood containing the blood to which at least one substance has been added to provide whole body reperfusion of the circulatory system with the modified blood during the treatment of the cardiac arrest, circulatory arrest or stroke comprising:

withdrawing the blood from the circulatory system during the treatment of the cardiac arrest, circulatory arrest or stroke;

analyzing the blood withdrawn from the circulatory system during the treatment of the cardiac arrest, circulatory arrest or stroke to determine a plurality of parameters of the blood including at least pO2, pCO2, and pH representing a current condition of the patient or animal during the treatment of cardiac arrest, circulatory arrest or stroke;

storing at least two substances from which at least one substance is selected to form the modified blood during the treatment of the cardiac arrest, circulatory arrest or stroke;

selecting, based on the determination of at least the pO2, the pCO2 and the pH, during the treatment of cardiac arrest, circulatory arrest or stroke, a type and quantity of at least one of the at least two stored substances which is added to the withdrawn blood to form the modified blood, which upon introduction into the circulatory system to provide whole body reperfusion of the circulatory system during the treatment of the cardiac arrest, circulatory arrest or stroke, lessens or prevents ischemic tissue damage during the treatment of the cardiac arrest, circulatory arrest or stroke; and

introducing the modified blood into the circulatory system to provides whole body reperfusion of the circulatory system during the treatment of the cardiac arrest, circulatory arrest or stroke, which lessens or prevents the ischemic tissue damage during the treatment of cardiac arrest, circulatory arrest or stroke.

42. A method in accordance with claim 41 comprising:

prior to addition of the modified blood, at least one substance is added to the circulatory system.